方盛製藥(603998.SH):諾麗通顆粒源於天津中醫藥大學第一附屬醫院臨牀經驗方
格隆匯6月16日丨有投資者向方盛製藥(603998.SH)提問:公司諾麗通顆粒與傳統的頭痛止痛類產品(布洛芬等)有什麼區別,諾麗通顆粒是不是屬於可以根治頭痛的產品?
方盛製藥回覆:諾麗通顆粒源於天津中醫藥大學第一附屬醫院臨牀經驗方,由經典方劑“升陷湯”加減化裁而來,適用於頻發性緊張型頭痛的創新中藥,以補氣養血,散風止痛立法,內外兼治,可有效縮短頭痛時間,減輕頭痛強度,降低頭痛發生頻率,藥效持久,安全性好;而布洛芬為非甾體抗炎藥,並非針對頭痛的藥物,不能減輕頭痛的發生頻率等。
緊張性頭痛,病因複雜,多呈反覆發作,且與生活習慣、心理因素等關係密切,臨牀治療以緩解疼痛強度、縮短疼痛時間、降低頭痛發生頻率、提高患者生活質量為治療目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.